2022
DOI: 10.1016/j.kint.2022.04.026
|View full text |Cite
|
Sign up to set email alerts
|

Lineage tracing analysis defines erythropoietin-producing cells as a distinct subpopulation of resident fibroblasts with unique behaviors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 17 publications
(7 citation statements)
references
References 33 publications
0
7
0
Order By: Relevance
“…When exposed to hypoxia, renin‐producing JG cells are converted to EPO‐producing cells (Broeker, Fuchs, et al., 2022; Kurt et al., 2013). Conversely, in rodent and human cases of pronounced interstitial fibrosis, myofibroblasts, which have lost their ability to synthetize EPO (Asada et al., 2011; Kaneko et al., 2022), start to produce renin (Miyauchi et al., 2021). This cell switch correlates with the increase in systemic blood pressure observed in patients suffering from chronic tubulointerstitial nephritis (Miyauchi et al., 2021).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…When exposed to hypoxia, renin‐producing JG cells are converted to EPO‐producing cells (Broeker, Fuchs, et al., 2022; Kurt et al., 2013). Conversely, in rodent and human cases of pronounced interstitial fibrosis, myofibroblasts, which have lost their ability to synthetize EPO (Asada et al., 2011; Kaneko et al., 2022), start to produce renin (Miyauchi et al., 2021). This cell switch correlates with the increase in systemic blood pressure observed in patients suffering from chronic tubulointerstitial nephritis (Miyauchi et al., 2021).…”
Section: Discussionmentioning
confidence: 99%
“…Induced pluripotent stem cell (iPS) technology offers new opportunities for both mechanistic studies and development of stem cell‐based therapies. Although it could be very challenging to revert renin‐producing myofibroblasts (Miyauchi et al., 2021) into EPO‐producing fibroblasts (Kaneko et al., 2022), one can envision stem cell‐based therapies using EPO‐producing cells from patient‐derived iPS cells. The conversion of iPS cells to NCCs has already been established (Chambers et al., 2009) and iPS generated from P0‐Cre transgene already exist (Ogawa et al., 2015).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…On the other hand, the dysregulated hematopoietic process is associated with organ damage in fibrotic diseases. Firstly, erythropoietin (Epo)-producing fibroblasts in the kidney transdifferentiate into myofibroblasts during kidney fibrosis, leading to anemia due to Epo deficiency [ 43 , 44 ]. Secondly, altered fibrosis-related cytokines, such as interleukin-6 (IL-6) and transforming growth factor-β (TGF-β), contribute to the deficiency and dysfunction of hematopoietic stem cells (HSCs) that ultimately result in decreased erythropoiesis [ 45 ].…”
Section: Discussionmentioning
confidence: 99%
“…We found that in aged, injured kidneys, fibroblasts have crucial roles in TLS formation and maturation 54 . In young, injured kidneys, resident fibroblasts transdifferentiate into scar-producing myofibroblasts at the cost of physiological erythropoietin production, leading to fibrosis and renal anaemia, which are common pathological conditions in CKD [172][173][174] . In aged, injured kidneys, fibroblasts also transdifferentiate into TLS-related heterogeneous fibroblasts with distinct phenotypes 7 (Fig.…”
Section: Chronic Inflammatory Diseases and Ageingmentioning
confidence: 99%